Neurocrine Biosciences
NBIX
#1412
Rank
HK$125.21 B
Marketcap
HK$1,245
Share price
-1.41%
Change (1 day)
34.31%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2026 (TTM): HK$52.40

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is HK$52.53. In 2025 the company made an earnings per share (EPS) of HK$37.74 an increase over its 2024 EPS that were of HK$26.46.

EPS history for Neurocrine Biosciences from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)HK$52.4038.86%
2025HK$37.7442.6%
2024HK$26.4633.07%
2023HK$19.8957.76%
2022HK$12.6169.47%
2021HK$7.44-78.21%
2020HK$34.14990%
2019HK$3.1381.82%
2018HK$1.72-113.5%
2017-HK$12.760.62%
2016-HK$12.6857.28%
2015-HK$8.0625.61%
2014-HK$6.4218.84%
2013-HK$5.40-1085.71%
2012HK$0.55

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
HK$10.26-80.48%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
HK$16.10-69.35%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
HK$220.98 320.65%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
HK$7.20-86.29%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
-HK$15.89-130.25%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
HK$27.40-47.84%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
-HK$234.10-545.60%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
HK$14.91-71.62%๐Ÿ‡ฌ๐Ÿ‡ง UK